Oscotec Inc.

With the long-awaited global commercialization of lazertinib, Oscotec Inc. and its US subsidiary Genosco, the originators of the novel lung cancer drug, are poised to see a steady inflow of revenues

A series of initial public offering plans unveiled by South Korean biopharma firms, notably Orum Therapeutics Inc., is raising hopes of a recovery in the general funding situation in the sector. After

Johnson & Johnson announced significant positive updated and new data for Rybrevant (amivantamab) with lazertinib in first-line non-small cell lung cancer (NSCLC) at the American Society of Clinical

With the launch of novel lung cancer drug Leclaza (lazertinib) in South Korea and other international approvals in sight, Yuhan Corporation is at the starting point of potentially evolving into a co